Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European journal of medicinal chemistry

• Publication date

  2018-05-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2018.04.046PMID 29738953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes

  2019cited by this paper
• Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

  2019cited by this paper
• Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.

  2018cited by this paper
• Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma

  2018cited by this paper
• Recent advances in the discovery of potent and selective HDAC6 inhibitors.

  2018cited by this paper
• Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.

  2017cited by this paper
• How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.

  2017cited by this paper
• Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors

  2017cited by this paper
• Histone deacetylase 6 structure and molecular basis of catalysis and inhibition

  2016cited by this paper
• Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells

  2016cited by this paper
• Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.

  2016cited by this paper
• Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors.

  2016cited by this paper
• Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases

  2015cited by this paper
• Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.

  2015cited by this paper
• A novel histone deacetylase 6‐selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody‐induced arthritis mouse model

  2015cited by this paper
• Panobinostat: First Global Approval

  2015cited by this paper
• Drugging the HDAC6-HSP90 interplay in malignant cells.

  2014cited by this paper
• Belinostat: First Global Approval

  2014cited by this paper
• Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.

  2014cited by this paper
• Design, synthesis, anti-TMV, fungicidal, and insecticidal activity evaluation of 1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid derivatives based on virus inhibitors of plant sources.

  2014cited by this paper
• Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.

  2013cited by this paper
• Identification of Novel Amino Acid Derived CCK-2R Antagonists As Potential Antiulcer Agent: Homology Modeling, Design, Synthesis, and Pharmacology

  2013cited by this paper
• SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation

  2013cited by this paper
• Development and therapeutic implications of selective histone deacetylase 6 inhibitors.

  2013cited by this paper
• Structural basis for the design and synthesis of selective HDAC inhibitors.

  2013cited by this paper
• Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes

  2012cited by this paper
• Indole-derived psammaplin A analogues as epigenetic modulators with multiple inhibitory activities.

  2012cited by this paper
• Development and therapeutic impact of HDAC6-selective inhibitors.

  2012cited by this paper
• First highly stereocontrolled synthesis of tetrahydro trans-β-carboline derivatives by exploiting the influence of a cyclic amide

  2012cited by this paper
• Histone deacetylase inhibitors (HDACIs). Structure—activity relationships: history and new QSAR perspectives

  2012cited by this paper
• Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells.

  2012cited by this paper
• HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.

  2012cited by this paper
• Romidepsin for cutaneous T-cell lymphoma.

  2012cited by this paper
• Targeting HDACs: A Promising Therapy for Alzheimer's Disease

  2011cited by this paper
• Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.

  2011cited by this paper
• Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.

  2011cited by this paper
• Chiral indolo[3,2-f][3]benzazecine-type dopamine receptor antagonists: synthesis and activity of racemic and enantiopure derivatives.

  2011cited by this paper
• Inhibitors of HDACs--effective drugs against cancer?

  2010cited by this paper
• Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation

  2010cited by this paper
• An Efficient and General Method for the Stereodivergent Syntheses of Tadalafil-Like Tetracyclic Compounds

  2010cited by this paper
• Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.

  2010cited by this paper
• HDAC2: a critical factor in health and disease.

  2009cited by this paper
• Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.

  2009cited by this paper
• HDAC family: What are the cancer relevant targets?

  2009cited by this paper
• The Cyclin-Dependent Kinase Inhibitor p21 Is a Crucial Target for Histone Deacetylase 1 as a Regulator of Cellular Proliferation

  2009cited by this paper
• Epigenetic control of skull morphogenesis by histone deacetylase 8.

  2009cited by this paper
• Syntheses of chiral 1,3-disubstituted tetrahydro-β-carbolines via CIAT process: highly stereoselective Pictet–Spengler reaction of d-tryptophan ester hydrochlorides with various aldehydes

  2009cited by this paper
• HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions.

  2008cited by this paper
• Highly stereoselective Pictet–Spengler reaction of d-tryptophan methyl ester with piperonal: convenient syntheses of Cialis (Tadalafil), 12a-epi-Cialis, and their deuterated analogues

  2008cited by this paper
• Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally

  2008cited by this paper
• Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice.

  2008cited by this paper
• Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.

  2007cited by this paper
• Racemization, optical resolution and crystallization-induced asymmetric transformation of amino acids and pharmaceutical intermediates.

  2007cited by this paper
• Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

  2007cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• Synthesis and cytotoxic activities of β-carboline amino acid ester conjugates

  2006cited by this paper
• Characterization of the two catalytic domains in histone deacetylase 6.

  2006cited by this paper
• Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors

  2005cited by this paper
• The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.

  2003cited by this paper
• Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

  2003cited by this paper
• HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo

  2003cited by this paper
• First stereoselective synthesis of 2-deoxy-alpha-D-ribosyl-1-phosphate: novel application of crystallization-induced asymmetric transformation.

  2002cited by this paper
• Identification of a Signal-Responsive Nuclear Export Sequence in Class II Histone Deacetylases

  2001cited by this paper
• Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods

  1998cited by this paper
• A second generation force field for the simulation of proteins

  1995cited by this paper
• Stereospecificity in the Reaction of Tetrahydro-.beta.-carboline-3-carboxylic Acids with Isocyanates and Isothiocyanates. Kinetic vs Thermodynamic Control

  1994cited by this paper
• A new approach to analysis and display of local lipophilicity/hydrophilicity mapped on molecular surfaces

  1993cited by this paper
• Synthesis of Enantiomerically Pure Tetrahydro-2-methylharman

  1993cited by this paper
• Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.

  1990cited by this paper
• Synthesis and Reactivity of β-Carboline-Hydantoin Systems

  1990cited by this paper
• Synthesis of β-carboline-benzodiazepine hybrid molecules and their “amputated” analogues as novel ligands of the benzodiazepine receptor

  1990cited by this paper
• Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester.

  1990cited by this paper
• Validation of the general purpose tripos 5.2 force field

  1989cited by this paper
• Syhthesis of pentacyclic β-carbolike and 1,4-benzodiazepine hybrid molecules by dehydrogenatioh-trahsamidation of quinazolino-tetrahydro-β-carbolines

  1987cited by this paper
• beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic acid.

  1983cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Agents acting on the central nervous system. 15. 2-Substituted 1,2,3,4,6,7,12,12a-octahydropyrazino(2',1':6,1)pyrido(3,4-b)indoles. A new class of central nervous system depressants.

  1973cited by this paper
• Epimeric forms of quaternary derivatives of atropine.

  1973cited by this paper
• AGENTS ACTING ON THE CENTRAL NERVOUS SYSTEM PART 15, 2-SUBSTITUTED 1,2,3,4,6,7,12,12A-OCTAHYDROPYRAZINO(2′,1′/6,1)PYRIDO(3,4-B)INDOLES, A NEW CLASS OF CENTRAL NERVOUS SYSTEM DEPRESSANTS

  1973cited by this paper
• Über die Bildung von Isochinolin‐derivaten durch Einwirkung von Methylal auf Phenyl‐äthylamin, Phenyl‐alanin und Tyrosin

  1911cited by this paper

• Serotonergic Psychedelics as Epigenetic Modulators: A Paradigm Shift in Alzheimer's Disease Therapeutics.

  2026cites this paper
• Modeling spastic paraplegia 4 with corticospinal motor neuron-enriched cortical organoids reveals genotype-phenotype and HDAC6-targetable pathology.

  2026cites this paper
• Pharmacologically induced proteolysis of histone deacetylase-6 attenuates influenza virus replication despite limited anti-tumor effects.

  2025cites this paper
• Genotype–Phenotype Distinctions in Spastic Paraplegia 4 Reveal HDAC6 as a Therapeutic Target

  2025cites this paper
• Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancer.

  2025cites this paper
• Epigenetic mechanisms of rapid-acting antidepressants

  2024cites this paper
• Synthesis of New Fluorinated Tubastatin A Derivatives Based on Cyclopentane/Cyclohexane with Good Anti‐tumor Activity in Vitro

  2024cites this paper
• Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity.

  2024cites this paper
• Synthesis, structure–activity relationship, and biological evaluation of quinolines for development of anticancer agents

  2023cites this paper
• Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity

  2023cites this paper
• Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design.

  2023cites this paper
• Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma.

  2022cites this paper
• Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.

  2022cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• HDAC6: A unique HDAC family member as a cancer target

  2022cites this paper
• Identification of HDAC10 Inhibitors that Modulate Autophagy-Related Proteins in Transformed Cells

  2022cites this paper
• Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer.

  2022cites this paper
• A review of synthetic bioactive tetrahydro-β-carbolines: A medicinal chemistry perspective.

  2021cites this paper
• A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.

  2021cites this paper
• An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives

  2021cites this paper
• Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition

  2021cites this paper
• Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

  2021cites this paper
• Post-translational lysine ac(et)ylation in health, ageing and disease

  2021influential citation
• Histone Modifications and Their Targeting in Lymphoid Malignancies

  2021influential citation
• Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).

  2020cites this paper
• Recent advances in small molecular modulators targeting histone deacetylase 6

  2020cites this paper
• Pegaharmols A-B, Axially Chiral β-Carboline-quinazoline Dimers from the Roots of Peganum harmala.

  2020cites this paper
• Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors.

  2020cites this paper
• Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.

  2020cites this paper
• Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

  2019cites this paper
• Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.

  2019cites this paper
• Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes

  2019cites this paper
• Next-generation of selective histone deacetylase inhibitors

  2019cites this paper
• Enantioselective synthesis and biological investigation of tetrahydro‐β‐carboline‐based HDAC6 inhibitors with improved solubility

  2019cites this paper
• Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma

  2018cites this paper
• Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.

  2018cites this paper
• Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors

  2018cites this paper